publication date: May. 3, 2019
NCI Trials NCI Trials for May
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
For further information, contact the principal investigator listed.
Phase I – 10204
A Phase Ib Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
University of Texas MD Anderson Cancer Center LAO
Tawbi, Hussein Abdul-Hassan
(713) 792-4185
Phase I – 10249
MLN9708 (Ixazomib) and MLN4924 (Pevonedistat) in Relapsed/Refractory Multiple Myeloma Patients: A Phase 1b Trial
JHU Sidney Kimmel Comprehensive Cancer Center LAO
Lonial, Sagar
(404) 778-3921
Phase I – ADVL1712
A Feasibility Trial of MLN4924 (Pevonedistat, TAK 924, IND# 142772) Given in Combination with Azacitidine, Fludarabine, and Cytarabine, in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia or Relapsed Myelodysplastic Syndrome.
Pediatric Early Phase Clinical Trial Network
Tarlock, Katherine G.
(206) 667-7121
Phase I/II – 10216
A Phase I/II Study of AZD9291(Osimertinib) and CB-839 HCl in Patients with EGFR Mutant Non-Small Cell Lung Cancer
Ohio State University Comprehensive Cancer Center LAO
Owen, Dwight Hall
(614) 685-2039
… Continue reading NCI Trials for May 2019
To access this members-only content, please log in.Institutional subscribers, please
log in with your IP.
If you're not a subscriber why not
join today? To gain access to the members only content
click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.
